

DAFTAR PUSTAKA

- Ahmed, AAM. 2014. Clinicopathological Profile of Female Sudanese Patients With Locally Advanced Breast Cancer. Faculty of Medicine. University of Medical Sciences and Technology. Khartoum. Sudan. *Breast Disease*. 10(25), pp. 1-4. Available on : <https://www.researchgate.net/publication/259846855>
- Akbar, M., Akbar, K., Naveed, D. (2014). Frequency And Correalation of Molecular Subtypes of Breast Cancer With Clinicopathological Features. *J Ayub Me Coll Abbottabad*, 26(3), 290-293. Available on <http://www.ayubmed.edu.pk/JAMC/26-3/Akbar.pdf>
- Ambrosone, C. B., Zirpoli, G., Hong, C. C., Yao, S., Troester, M. A., Bandera, E. V., . . . Palmer. (2015). Important Role of Menarche in Development of Estrogen Receptor–Negative Breast Cancer in African American Women. *Journal of National Cancer Institute*, 107(9), 1-7.
- American Joint Committee on Cancer. (2017). AJCC Cancer Staging Manual, Eight Edition. *The American College of Surgeons*.
- American Cancer Society. (2017). Breast Cancer Facts & Figures 2017-2018. Atlanta : American Cancer Society Inc.
- American Institute for Cancer Research. (1997). Food, nutrition and the prevention of cancer: a global perspective American Institute for Cancer Research. Washington DC.
- Anggraeni, DR, 2011. *Hubungan Antara Faktor Usia Dengan Angka Kejadian Carcinoma Mammae Dri RSUD dr. Moewardi Surakarta*. Karya Tulis Ilmiah. Fakultas Kedokteran Universitas Muhammadiyah. Surakarta.
- Asano, Y, Kashiwagi, S, Goto, W, et al. 2017. Prediction of Survival After Neoadjuvant Chemotherapy for Breast Cancer by Evaluation of Tumor-Infiltrating Lymphocytes and Residual Cancer Burden. *BMC Cancer*. 17, pp. 888
- Bae, SY, Lee, SK, Koo, MY, et al. 2011. The Prognosis of Metaplastic Breast Cancer Patients Compared to Those of Triple-Negative Breast Cancer Patients. *Breast Cancer Res Treat*. 126, pp. 471-478.
- Buzdar, A. et al., 1999. Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. *Journal of Clinical Oncology*, 17(11), p. 3412.
- Bessaoud, F., Daures, J.-P. & Gerber, M., 2008. Dietary Factors and Breast Cancer Risk: A Case Control, Study Among a Population in Southeastern France. *Nutrition and Cancer*, 60(2), pp. 177-187.
- Campbell, JI, Yau, C, Krass, P, et al. 2017. Comparison of Residual Cancer Burden, American Joint Committee on Cancer Staging and Pathological Complete Response in Breast Cancer After Neoadjuvant Chemotherapy: Results from I-

SPY 1 TRIAL (CALGB 150005/150012; ACRIN 6657. *Breast Cancer Res Treat.* 165(1), pp 181-191

- Cejalvo, M.J., Pascual, T., Fernández-Martínez, A., Brasó-Maristany, F., Gomis, R.R., Perou, C.M., Muñoz, M., Prat, A., (2018). Clinical implications of the non-luminal intrinsic subtypes in hormone receptor-positive breast cancer, *Cancer Treatment Reviews* *Cancer Treatment Reviews*, doi: <https://doi.org/10.1016/j.ctrv.2018.04.015>
- Chakravarthy, A. B. et al., 2006. Neoadjuvant Concurrent Paclitaxel and Radiation in Stage II/III Breast Cancer. *Clinical Cancer Research*, 12(5), pp. 1570-1576.
- Chan, D. S., & Norat, T. (2015). Obesity and Breast Cancer: Not Only a Risk Factor of the Disease. *Curr. Treat. Options in Oncol.*, 16(22), 1-17.
- Chen, A. M., Meric-Bernstam, F., Hunt, K. K., Thames, H. D., Oswal, M. J., Outlaw, E. D., . . . Perkin. (2004, June 15). Breast Conservation After Neoadjuvant Chemotherapy: The M.D. Anderson Cancer Center Experience. *Journal of Clinical Oncology*, 22(12), 2303-2312.
- Cheng, P., Huang, Q., Shou, J., Hu, G., Han, M., & Huang, J. (2017, October 3). Treatment and survival outcomes of lobular carcinoma in situ of the breast: a SEER population based study. *Oncotarget*, 8(61), 103047-103054. Diambil kembali dari www.impactjournals.com/oncotarget/
- Cianfrocca, M., & Goldstein, L. J. (2004). Prognostic and Predictive Factors in Early-Stage Breast Cancer. *The Oncologist*.
- Collaborative Group on Hormonal Factors in Breast Cancer. (2012). Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies. *The Lancet Oncology*, 13(11), 1141-1151.
- Corben, AD, Abi-Raad, R, Popa, I, et al. 2013. Pathologic Response and Long-Term Follow-up in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: A Comparison Between Classification and Their Practical Application. *Archives of Patholgy and Laboratory Medicine*. 137, pp. 1074-1082.
- Dai, X., Bai, T. L., Zhonghu, Yang, Y., Liu, X., Zhan, J., & Shi, B. (2015). Breast cancer intrinsic subtype classification, clinical use and future trends. *American Journal of Cancer*, 5(10), 2929-2943.
- Desmedt, C., Zoppoli, G., Gudem, G., Pruneri, G., Larsimont, D., Fornili, M., . . . Metzger, O. (2016, June 1). Genomic Characterization of Primary Invasive Lobular Breast Cancer. *Journal of Clinical Oncology*, 34(16), 1872-1881. doi:10.1200/JCO.2015.64.0334
- Duffy, M. J., Harbeck, N., Nap, M., Molina, R., Nicolini, A., Senkus, E., & Cardoso, F. (2017). Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM). *European Journal of Cancer*, 75, 2017284-298.
- Egwuonwu OA, Anyanwu SN, Nwofor AM. (2013). Efficacy of neoadjuvant chemotherapy in down staging locally advanced pre-menopausal breast cancer

- in Eastern Nigeria: Is four courses adequate?. *J Can Res Ther.* 9(4), p. 638-643. Available from: <http://www.cancerjournal.net/text.asp?2013/9/4/638/126463>
- Ellis, I. O. et al., 2003. Invasive Breast Carcinoma. In: F. A. Tavasoli & P. Devilee, eds. *Pathology & Genetics of Tumours of The Breast and Female Genital Organ*. Lyon: IARC Press, p. 13.
- Elston, CW. 1984. The Assessment of Histological Differentiation in Breast Cancer. *Aust. N.Z. J. Surg.* 54, pp 11-15.
- Errahhali, M. E., Errahhali, M. E., Ouarzane, M., Harroudi, T. E., & Afqir, S. (2017). First report on molecular breast cancer subtypes and their clinico-pathological characteristics in Eastern Morocco: series of 2260 cases. *BMC Women's Health* , 17(3), 1-11.
- Ferlicot, S., Vincent-Salomon, A., Medioni, J., Genin, P., Rosty, C., Sigal-Zafrani, B., . . . Sastre-Garau, X. (2004, August 12). Wide metastatic spreading in infiltrating lobular carcinoma of the breast. *European Journal of Cancer*, 40, 336–341. doi:10.1016/j.ejca.2003.08.007
- Faneyte, I. F. et al., 2003. Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome. *British Journal of Cancer*, Volume 88, pp. 406-412.
- Firdaus, V. R. P., Asri, A., Khambri, D. & Harahap, W. A., 2016. Hubungan Grading Histopatologi dan Infiltrasi Limfovaskular dengan Subtipe Molekuler pada Kanker Payudara Invasif di Bagian Bedah RSUP. Dr. M. Djamil Padang. *Jurnal Kesehatan Andalas*, 5(1), pp. 165-172.
- Fishman, J., Fukushima, D., O'connor, J., Rosenfeld, R. S., Lynch, H. T., Lynch, J. F., & Hoda, G. M. (1978). Plasma Hormone Profiles of Young Women at Risk for Familial Breast Cancer. *Cancer Research*, 38, 4006-4011.
- Ghonchek, M., Pournamdar, Z., & Salehiniya, H. (2016). Incidence and Mortality and Epidemiology of Breast Cancer in the World. *Asian Pac J Cancer Prev*, 17, 43-46.
- Gogoi, G. 2016. Profile of Molecular Subtypes of Breast Cancer with Special Reference to Triple Negative: A Study from Northeast India. *Clinical Cancer Investigation Journal*. 5(5), pp. 374-383.
- Goldhirsch, A. et al., 2011. Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. *Annals of Oncology*, Volume 22, p. 1736–1747.
- Hanan, DM. 2017. *Hubungan Klinis dan Patologis Pasien Dengan Kanker Payudara di RSUD Dr. Soetomo Tahun 2015*. Karya Tulis Ilmiah, Fakultas Kedokteran Universitas Airlangga. Surabaya.
- Hariroh, NA. 2017. *Hubungan Tingkat Gejala Depresi dengan Stadium Kanker Payudara di Poli Onkologi Satu Atap (POSA) RSUD Dr. Soetomo Surabaya*. Karya Tulis Ilmiah. Fakultas Kedokteran Universitas Airlangga. Surabaya.

- Haybittle, JI, Blamey, RW, Elston, CW, et al. 1982. A Prognostic Index in Primary Breast Cancer. *British Journal of Cancer*. 45, pp 361-366.
- Hortobagyi, G. (2005, May 27). Neoadjuvant treatment: the MD Anderson experience. *Breast Cancer Research*, 7(1), S18. doi: 10.1186/bcr1222
- Houssami, N, Macaskill, P, Minckwitz, G, et al. 2012. Meta-analysis of The Association of Breast Cancer Subtype and Pathologic Complete Response to Neoadjuvant Chemotherapy. *European Journal of Cancer*. 48, pp. 3342-3354.
- Irwan, Azamris, Bachtiar, H. 2015. Perbandingan Prognosis Subtipe Molekuler Kanker Payudara Antara Pasien Kanker Payudara Wanita Usia dan Tua di RSUP Dr. M. Djamil Padang. *Majalah Keokteran Andalas*. 38(3), pp. 208-217.
- Inwald, E. C., Klinkhammer-Schalke, M., Hofstadter, M., Zeman, F., & Koller, M. (2013). Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry. *Breast Cancer Res Treat*, 139, 539-552.
- Joensuu, K., Leidenius, M., Kero, M., Andersson, L. C., Horwitz, K. B., & Heikkila, P. (2013). ER, PR, HER2, Ki-67 and cK5 in Early and Late Relapsing Breast cancer—Reduced CK5 Expression in Metastases. *Libertas Academica*, 7, 23-24.
- Kaaks, R., Kaja, T., Sookthai, D., Schock, H., Johnson, T., Tjonneland, A., . . . Boeing, H. (2014). Premenopausal serum sex hormone levels in relation to breast cancer risk, overall and by hormone receptor status—Results from the EPIC cohort. *International Journal of Cancer*, 134, 1947-1957.
- Karakas, C. (2011). Paget's disease of the breast. *Journal of Carcinogenesis*, 10(31). doi: 10.4103/1477-3163.90676
- Katzung, B. G., Masters, S. B. & Trevor, A., 2014. *Farmakologi Dasar & Klinik, Vol 2*. 12 ed. Jakarta: Penerbit Buku Kedokteran EGC.
- Kim, J. H., Lee, J., Jung, S. Y., & Kim, J. (2017). Dietary Factors and Female Breast Cancer Risk: A Prospective Cohort Study. *Nutrients*, 9, 1331.
- King, T. A., Pilewskie, M., Muhsen, S., Patil, S., Mautnerr, S. K., Park, A., . . . Morrow. (2015, November 20). Lobular Carcinoma in Situ: A 29-Year Longitudinal Experience Evaluating Clinicopathologic Features and Breast Cancer Risk. *JOURNAL OF CLINICAL ONCOLOGY*, 33(33), 3945-3956.
- Krishnamurti, U., & Silverman, J. F. (2014). HER2 in breast cancer: a review and update. *Adv Anat Pathol* , 21, 100-107.
- Kroman, N., Wohlfahrt, J., Andersen, K. W., Mourisen, H., Westergaard, T., & Melbye, M. (1998). Parity, age at first childbirth and the prognosis of primary breast cancer. *British Journal of Cancer*, 78(11), 1529-1533.
- Kumar, V, Tewari, M, Singh, U, Shukla, HS. 2007. Significance of Her-2/neu Protein Over Expression in Indian Breast Cancer Patients. *Indian Journal of Surgical*. 69, p. 122-128.

- Lakhani S, Ellis I, Schnitt S, et al. 4th. *WHO Classification of Tumours of the Breast*. Lyon: IARC Press; 2012.
- Lee, HJ, Song, IH, Seo, AN, et al. 2014. Correlations Between Molecular Subtypes and Pathologic Response Patterns of Breast Cancers After Neoadjuvant Chemotherapy. *Annals of Surgical Oncology*. 22(2), pp. 392-400.
- Ligibel, J. M. (2011). Obesity and Breast Cancer. *Oncology Journal, Breast Cancer*, 25(11), 1-3. Diambil kembali dari <http://www.cancernetwork.com/oncology-journal/obesity-and-breast-cancer/page/0/2>
- Lim, S. K., Lee, M. H., Park, H. I., You, J. Y., Nam, B.-H., Kim, B. N., . . . Lee, E. S. (2016). Impact of Molecular Subtype Conversion of Breast Cancers after Neoadjuvant Chemotherapy on Clinical Outcome. *Cancer Research and Treatment*, 48(1), 133-141. doi: <https://doi.org/10.4143/crt.2014.262>
- Luangdilok, S., Samarthai, N., & Korphaisarn, K. (2014). Association between Pathological Complete Response and Outcome Following Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer Patients. *Journal of Breast Cancer*, 17(4), 376-385.
- MacMahon, B., Cole, P., Lin, T. N., Lowe, C. L., Mirra, A. P., Ravnihar, B., . . . Yuasa, S. (1970). Age at First Birth and Breast Cancer Risk. *Bull. Org. mond. Sante Bull. Wld Hlth Org*, 43, 209-221.
- Makki, J. 2015. Diversity of Breast Carcinoma: Histological Subtypes and Clinical Relevance. *Clinical Medicine Insights: Pathology*. 8, pp 23-31.
- McPherson, K., Steel, C. M. & Dixon, J. M., 2000. Breast cancer—epidemiology, risk factors, and genetics. *British Medical Journal*, Volume 321, pp. 624-628.
- Molina, R., Barak, V., Dalen, A. v., Duffy, M. J., Einarsson, R., Gion, M., . . . Stieber, P. (2005). Tumor Markers in Breast Cancer – European Group on Tumor Markers Recommendations. *Tumor Biology*, 26, 281-293.
- Nahleh, Z, Sivasubramaniam, D, Dhaliwal, S, Sundarajan, V, Komrokji, R. 2008. Residual Cancer Burden in Locally Advanced Breast Cancer: A Superior Tool. *Current Oncology*. 15(6), p. 17-24.
- National Comprehensive Cancer Network. (2006). Breast Cancer: Treatments Guideline for Patients. American Cancer Society.
- Ooe, A, Takahara, S, Sumiyoshi, K, et al. 2013. Relationship Between Intrinsic Subtypes and Tumor Responses to Neoadjuvant Chemotherapy in Patients With Locally Advanced Breast Cancer. *Breast Cancer*. 34, p. 9-17.
- Parise, CA, dan Caggiano, V. 2014. Breast Cancer Survival Defined by the ER/PR/HER2 Subtypes and a Surrogate Classification accoring to Tumor Grade and Immunohistochemical Biomarkers. *Journal of Cancer Epidemiology*., p. 11
- Perou, C. M., Sorlie, T., Eisen, M. B., Rijn, M. v., Jeffrey, S. S., Rees, C. A., . . . Zhu. (2000). Molecular portraits of human breast tumor. *Nature*, 406, 747-752.

- Picon-Ruiz, M., Morata-Tarifa, C., Valle-Goffin, J. J., Friedman, E. R., & Slingerlan, J. M. (2017). Obesity and Adverse Breast Cancer Risk and Outcome: Mechanistic Insights and Strategies for Intervention. *A Cancer Journal for Clinicians*, 67(5), 378-397.
- Prat, A, Fan, C, Fernandez, A, Hoadley, KA, et al. 2015. Response and Survival of Breast Cancer Intrinsic Subtypes Following Multi-agent Neoadjuvant Chemotherapy. *BMC Medicine*. 13(303), p. 1-11.
- Purnawaty, A. 2018. *Hubungan Subtipe Intrinsik dengan Respon Kemoterapi Neoadjuvan Regimen Berbasis Antrasiklin Pada Kanker Payudara Stadium Lanjut Lokal*. Tesis. Universitas Hasanuddin. Makassar.
- Rahman, MZ, Karim, A. 2017. Profile of Molecular Subtypes of Breast Cancer Among Bangladesh Women - Audit of Initial Experience. *Bangladesh Journal Online*. 16(2).
- Rahmatya, A, Khambri, D, Mulyani, H. 2015. Hubungan Usia dengan Gambaran Klinikopatologi Kanker Payudara di Bagian Bedah RSUP Dr. M. Djamil Padang. *Jurnal Kesehatan Andalas*. 4(2), pp. 478-484. Available on <http://jurnal.fk.unand.ac.id>
- Rahmawati, Y, Setyawati, Y, Wiodo, I, Ghozali, A, Purnomosari, D. 2017. Molecular Subtypes of Indonesian Breast Carcinomas - Lack of Association with Patient Age and Tumor Size. *Asian Pacific Journal of Cancer*. 199(1), pp. 161-166.
- Rakha, EA, Reis-Filho, JS, Baehner, F, et al. 2010. Breast Cancer Prognostic Classification in The Molecular Era: The Role of Histological Grade. *Breast Cancer Research*. 12(207), p. 1-12.
- Reed, A. E., Kutasovic, J. R., Lakhani, S. R., & Simpson, P. T. (2015, January 30). Invasive lobular carcinoma of the breast: morphology, biomarkers and 'omics. *Breast Cancer Research*, 17(1), 12. doi: 10.1186/s13058-015-0519-x
- Robertson, S., Rönnlund, C., de Boniface, J. et al. (2019). Re-testing of predictive biomarkers on surgical breast cancer specimens is clinically relevant. *Breast Cancer Res Treat*. 174(3), p. 795-805. Available on <https://link.springer.com/article/10.1007%2Fs10549-018-05119-2>
- Rossi, R. E., Pericleous, M., Mandair, D., Whyand, T., & Caplin, M. E. (2014). The Role of Dietary Factors in Prevention and Progression of Breast Cancer. *Anticancer Research*, 34, 6861-6876.
- Schwartz, TL, Mogal, H, Papageorgiou, C, Veerapong, J, Hsueh, EC. 2013. Metaplastic Breast Cancer: Histologic Characteristics, Prognostic Factors and Systemic Treatment Strategies. *Experimental Hematology & Oncology*. 2(31), p. 1-6.
- Shah, V., Nowinski, S., Levi, D., Shinomiya, I., Chaabouni, N. K., Gillett, C., . . . Sawyer, E. J. (2017). PIK3CA mutations are common in lobular carcinoma in situ, but are not a biomarker of progression. *Breast Cancer Research*, 19(7), 1-14.

- Simatupang, EMD. 2017. *Gambaran Histopatologi Kanker Payudara Duktal Invasif Berdasarkan Grading Pada Perempuan Usia 40 Tahun Kebawah Di RSUP Haji Adam Malik Medan Periode 2014-2106*. Karya Tulis Ilmiah. Fakultas Kedokteran. Universitas Sumatera Utara. Medan.
- Sinn, H.-P., & Kreipe, H. (2013, May). A Brief Overview of the WHO Classification of Breast Tumors, 4th Edition, Focusing on Issues and Updates from the 3rd Edition. *Breast Care (Basel)*, 8(2), 149–154. doi: 10.1159/000350774
- Siziopikou, K. P. (2013, April). Ductal Carcinoma In Situ of the Breast: Current Concepts and Future Directions. *Archives of Pathology & Laboratory Medicine*, 137(4), 462-466.
- Soediro, R, Nugroho, RS, Gondhowiarjo, SA. 2010. Karakteristik Subtipe Kanker Payudara Berdasarkan Status Hormonal dan Her-2. *Radioterapi & Onkologi Indonesia*. 1(2), p. 43-47.
- Soliman, N. A., & Yussif, S. M. (2016). Ki-67 as a prognostic marker according to breast cancer molecular subtype. *Cancer Biology an Medicine*, 13(4), 496-504.
- Strenger, M. (2013). Effects of Menarche and Menopause on Breast Cancer Risk: Meta-analysis Findings. Diambil kembali dari <http://www.ascopost.com/issues/april-15-2013/effects-of-menarche-and-menopause-on-breast-cancer-risk-meta-analysis-findings/>
- Sundquist, M, Thorstenson, S, Brudin, L, Nordenskjold, B. 1999. Applying the Nottingham Prognostic Index to a Swedish Breast Cancer Population: South East Swedish Breast Cancer Study Group. *Breast Cancer Res Treat* 53 (1), pp. 1-8.
- Suyatno, Pasaribu, ET. 2009. *Bedah Onkologi Diagnostik dan Terapi*. Jakarta: Sagung Seto.
- Syafri, M, Rachmawati, M, Istuti, RDI. 2015. Karakteristik Penderita Kanker Payudara Berdasarkan Gambaran Histopatologi di RSUD Al-Ihsan Bandung Periode 2011-2014. *Prosiding Penelitian Sivitas Akademika Unisba (Kesehatan)*. 2, pp. 821-828.
- Symmans, WF, Wei, C, Gould, R, et al. 2017. Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype. *Journal of Clinical Oncology*. 35(10), p. 1049-1060.
- Tan, EY, Ang, BK, Wong, HB, Chan, MYP. 2005. Locally Advanced and Metastatic Breast Cancer in a Tertier Hospital. *Annals of The Academy of Medicine*. 34(10), pp. 595-601.
- Togatorop, MP. 2014. *Hubungan Antara Grading Histopatologi dengan Ekspresi Ki-67 Penderita Kanker Payudara di Rumah Sakit Haji Adam Malik Medan*. Departemen Ilmu Bedah. Fakultas Kedokteran Universitas Sumatera Utara. Medan.

- Vecchia, C. L., Decarli, A., Franceschi, S., Gentile, A., Negri, E., & Parazzini, F. (1987). Dietary Factors and the Risk of Breast Cancer. *Nutrition and Cancer*, 10(4), 205-214. doi: 10.1080/01635588709513958
- Vidiyanti, C, Fauziah, D, Suprabawati, DGA. 2014. ER, PR, And Her2/Neu Profile on Young Breast Carcinoma Patients. *Folia Medica Indonesiana*. 50(1), pp.15-18.
- Virnig, B. A., Tuttle, T. M., Shamliyan, T., & Kane, R. L. (2010, February 3). Ductal Carcinoma In Situ of the Breast: A Systematic Review of Incidence, Treatment, and Outcomes. *J Natl Cancer Inst*, 102(3), 170-178.
- Walker, RA, dan Thompson, A. 2008. Prognostic and Predictive Factors in Breast Cancer. United Kingdom. *Informa Healthcare*
- Wangsa, IGMS, Niryana, IW, Adiputra, PAT, Dewi, NPAPA. 2018. Gambaran Stadium dan Jenis Histopatologi Kanker Payudara di Subbagian Bedah Onkologi RSUP Sanglah Denpasar tahun 2015-2016. *Intisari Sains Medis*. 9(1), pp. 80-84.
- Warwick, J, Tabar, L, Vitak, B, uffy, SW, et al. 2004. Time-Dependent Effects on Survival in Breast Carcinoma: Results of 20 Years of Follow-Up from Swedish Two-County Study. *Cancer*. 100(7), pp. 1331-1336.
- Weihuaa, Z., Anderssona, S., Chenga, G., Simpsonb, E. R., Warnera, M., & Gustafsson, J.-A. (2003). Update on estrogen signaling. *FEBS Letters*, 546, 17-24.
- Widodo, I, Dwianingsih, EK, Anwar, SL, et al. 2017. Prognostic Value of Clinicopathological Factors for Indonesian Breast Carcinomas of Different Molecular Subtypes. *Asian Pacific Journal of Cancer Prevention*. 18(5), pp. 1251-1256.
- World Health Organization, 2014. *Cancer Country Profiles*, s.l.: s.n.
- Xue, C, Wang, X, Peng, R, et al. 2012. Distribution, Clinicopathologic Features and Survival of Breast Cancer Subtypes in Southern China. *Cancer Science*. 103(9), pp. 1679-1687.
- Yamauchi, H., Woodward, W. A., Valero, V., Alvarez, R. H., Lucci, A., Buchholz, T. A., . . . Ueno, N. T. (2012). Inflammatory Breast Cancer: What We Know and What We Need to Learn. *The Oncologist*, 17(7), 891-899.
- Yang, L.-Y., Yang, L.-P., & Zhu, B. (2017, September 26). Clinicopathological characteristics and survival outcomes of invasive lobular carcinoma in different races. *Oncotarget*, 8(43), 74287–74298. doi: 10.18632/oncotarget.19396
- Yip, C.-H., & Rhodes, A. (2014). Estrogen and progesterone receptors in breast cancer. *Future Oncology*, 10(14), 2293-2301.
- Yulianti, I., Setyawan, H. & Sutningsih, D., 2016. FAKTOR-FAKTOR RISIKO KANKER PAYUDARA (Studi Kasus Pada Rumah Sakit Ken Saras Semarang). *Jurnal Kesehatan Masyarakat*, 4(4), pp. 401-409.

- Zahi Mitri, Z., Constantine, T., & O'Regan, R. (2012). *The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in Therapy*. USA: Hindawi Publishing Corporation.
- Zhao, Y, Dong, X, Li, R, Ma, X, Song, J, Li, Y, Zhang, D. 2015. Evaluation of The Pathological Response and Prognosis Following Neoadjuvant Chemotherapy in Molecular Subtypes of Breast Cancer. *Onco Targets and Therapy*. 8, pp 1511-1521.